Janney Montgomery Scott LLC lowered its stake in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 2.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,375 shares of the company’s stock after selling 1,059 shares during the period. Janney Montgomery Scott LLC’s holdings in Ionis Pharmaceuticals were worth $1,773,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Ionis Pharmaceuticals by 2.1% during the 2nd quarter. Vanguard Group Inc. now owns 12,306,251 shares of the company’s stock worth $725,576,000 after acquiring an additional 252,690 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Ionis Pharmaceuticals by 6.3% in the 3rd quarter. First Trust Advisors LP now owns 1,397,713 shares of the company’s stock worth $66,321,000 after buying an additional 82,506 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Ionis Pharmaceuticals by 6.1% in the 2nd quarter. Goldman Sachs Group Inc. now owns 763,778 shares of the company’s stock worth $45,032,000 after buying an additional 44,028 shares during the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Ionis Pharmaceuticals by 6.8% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 715,880 shares of the company’s stock worth $42,209,000 after buying an additional 45,742 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its position in Ionis Pharmaceuticals by 0.9% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 616,469 shares of the company’s stock valued at $36,348,000 after purchasing an additional 5,770 shares during the last quarter. 85.39% of the stock is currently owned by institutional investors.
In other news, Director Joseph Klein III sold 2,889 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, October 20th. The stock was sold at an average price of $46.86, for a total transaction of $135,378.54. Following the sale, the director now directly owns 13,794 shares of the company’s stock, valued at $646,386.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider C Frank Bennett sold 15,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $46.77, for a total value of $701,550.00. Following the sale, the insider now directly owns 47,476 shares in the company, valued at $2,220,452.52. The disclosure for this sale can be found here. Insiders have sold 20,203 shares of company stock valued at $954,150 in the last three months. Insiders own 2.40% of the company’s stock.
Shares of IONS opened at $49.14 on Friday. The stock has a market capitalization of $6.87 billion, a P/E ratio of 102.38 and a beta of 1.44. Ionis Pharmaceuticals, Inc. has a twelve month low of $39.32 and a twelve month high of $66.22. The company has a 50 day moving average of $47.87 and a 200-day moving average of $53.97. The company has a quick ratio of 10.84, a current ratio of 10.94 and a debt-to-equity ratio of 0.50.
Ionis Pharmaceuticals (NASDAQ:IONS) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.11). Ionis Pharmaceuticals had a net margin of 7.82% and a return on equity of 6.56%. The company had revenue of $160.00 million during the quarter, compared to analyst estimates of $182.14 million. During the same period in the previous year, the company posted $0.18 EPS. The company’s quarterly revenue was down 4.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Ionis Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.
IONS has been the topic of a number of recent analyst reports. William Blair restated a “hold” rating on shares of Ionis Pharmaceuticals in a research report on Wednesday, August 5th. SVB Leerink dropped their target price on shares of Ionis Pharmaceuticals from $56.00 to $50.00 and set a “market perform” rating on the stock in a research report on Thursday, November 5th. Cantor Fitzgerald lifted their target price on shares of Ionis Pharmaceuticals from $56.00 to $59.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 22nd. BidaskClub cut shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 8th. Finally, Needham & Company LLC raised their price target on shares of Ionis Pharmaceuticals from $89.00 to $91.00 and gave the stock a “buy” rating in a report on Tuesday, September 1st. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $66.58.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy.
Read More: Pattern Day Trader – What is the PDT Rule?
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS).